This site is intended for health professionals only
Sunday 16 June 2019
Share |

Psychiatric drug nears approval

US health chiefs have said that an experimental psychiatric drug appears to be a safe and effective treatment for people suffering from schizophrenia and bipolar disorder.

The Food and Drug Administration (FDA) said that Saphris, from health care firm Schering-Plough, appears to be as safe as other drugs in the class, known as atypical antipsychotics. The regulator, however, has not yet reached a final decision on the drug.

A panel of independent experts in the field of psychiatry will vote whether the FDA should approve the drug. The agency does not have to follow the panel's guidance but it usually does.

Schering-Plough held four studies into the effects of Saphris on schizophrenia patients. Two of the studies produced positive results, according to the FDA. It also studied the drug in two trials of bipolar patients, both of which showed positive results.

The drug's most common side effects emerged as sleepiness, restlessness, dizziness and weight gain.

If approved, Saphris would enter the market occupied by already established products such as AstraZeneca's Seroquel and Eli Lilly's Zyprexa, both of which are already approved for schizophrenia and bipolar disorder.

Copyright Press Association 2009

Food and Drug Administration

Ads by Google

You are leaving

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?


Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.



Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher